Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib

Samuel Taylor, Johanna Duyvestyn, Samantha Zeps, Emma Dishington, Catherine Rinaldi, Oliver M. Dovey, George Vassiliou, Carolyn Grove, Wallace Langdon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Here we describe an approach to inhibit chemotherapy-induced myelosuppression. We found that short-term exposure of mice to the FLT3 inhibitor quizartinib induced the transient quiescence of multipotent progenitors (MPPs). This property of quizartinib conferred marked protection to MPPs in mice receiving fluorouracil or gemcitabine. The protection resulted in the rapid recovery of bone marrow and blood cellularity, thus preventing otherwise lethal myelosuppression. A treatment strategy involving quizartinib priming that protected wild type bone marrow progenitors, but not leukemic cells, from fluorouracil provided a more effective treatment than conventional induction therapy in mouse models of acute myeloid leukemia. This strategy has the potential to be extended for use in other cancers where FLT3 inhibition does not adversely affect the effectiveness of chemotherapy. Thus, the addition of quizartinib to cancer treatment regimens could markedly improve cancer patient survival and quality of life.
Original languageEnglish
Article numberaam8060
Number of pages14
JournalScience Translational Medicine
Volume9
DOIs
Publication statusPublished - 9 Aug 2017

Fingerprint

Drug Therapy
gemcitabine
Fluorouracil
Bone Marrow
Neoplasms
Therapeutics
Acute Myeloid Leukemia
Quality of Life
Survival
quizartinib

Cite this

Taylor, Samuel ; Duyvestyn, Johanna ; Zeps, Samantha ; Dishington, Emma ; Rinaldi, Catherine ; Dovey, Oliver M. ; Vassiliou, George ; Grove, Carolyn ; Langdon, Wallace. / Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. In: Science Translational Medicine. 2017 ; Vol. 9.
@article{ab5b52ca37ad4cb288126cda593844ea,
title = "Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib",
abstract = "Here we describe an approach to inhibit chemotherapy-induced myelosuppression. We found that short-term exposure of mice to the FLT3 inhibitor quizartinib induced the transient quiescence of multipotent progenitors (MPPs). This property of quizartinib conferred marked protection to MPPs in mice receiving fluorouracil or gemcitabine. The protection resulted in the rapid recovery of bone marrow and blood cellularity, thus preventing otherwise lethal myelosuppression. A treatment strategy involving quizartinib priming that protected wild type bone marrow progenitors, but not leukemic cells, from fluorouracil provided a more effective treatment than conventional induction therapy in mouse models of acute myeloid leukemia. This strategy has the potential to be extended for use in other cancers where FLT3 inhibition does not adversely affect the effectiveness of chemotherapy. Thus, the addition of quizartinib to cancer treatment regimens could markedly improve cancer patient survival and quality of life.",
author = "Samuel Taylor and Johanna Duyvestyn and Samantha Zeps and Emma Dishington and Catherine Rinaldi and Dovey, {Oliver M.} and George Vassiliou and Carolyn Grove and Wallace Langdon",
year = "2017",
month = "8",
day = "9",
doi = "10.1126/scitranslmed.aam8060",
language = "English",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "AMER ASSOC ADVANCEMENT SCIENCE",

}

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. / Taylor, Samuel; Duyvestyn, Johanna; Zeps, Samantha; Dishington, Emma; Rinaldi, Catherine; Dovey, Oliver M.; Vassiliou, George ; Grove, Carolyn; Langdon, Wallace.

In: Science Translational Medicine, Vol. 9, aam8060, 09.08.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib

AU - Taylor, Samuel

AU - Duyvestyn, Johanna

AU - Zeps, Samantha

AU - Dishington, Emma

AU - Rinaldi, Catherine

AU - Dovey, Oliver M.

AU - Vassiliou, George

AU - Grove, Carolyn

AU - Langdon, Wallace

PY - 2017/8/9

Y1 - 2017/8/9

N2 - Here we describe an approach to inhibit chemotherapy-induced myelosuppression. We found that short-term exposure of mice to the FLT3 inhibitor quizartinib induced the transient quiescence of multipotent progenitors (MPPs). This property of quizartinib conferred marked protection to MPPs in mice receiving fluorouracil or gemcitabine. The protection resulted in the rapid recovery of bone marrow and blood cellularity, thus preventing otherwise lethal myelosuppression. A treatment strategy involving quizartinib priming that protected wild type bone marrow progenitors, but not leukemic cells, from fluorouracil provided a more effective treatment than conventional induction therapy in mouse models of acute myeloid leukemia. This strategy has the potential to be extended for use in other cancers where FLT3 inhibition does not adversely affect the effectiveness of chemotherapy. Thus, the addition of quizartinib to cancer treatment regimens could markedly improve cancer patient survival and quality of life.

AB - Here we describe an approach to inhibit chemotherapy-induced myelosuppression. We found that short-term exposure of mice to the FLT3 inhibitor quizartinib induced the transient quiescence of multipotent progenitors (MPPs). This property of quizartinib conferred marked protection to MPPs in mice receiving fluorouracil or gemcitabine. The protection resulted in the rapid recovery of bone marrow and blood cellularity, thus preventing otherwise lethal myelosuppression. A treatment strategy involving quizartinib priming that protected wild type bone marrow progenitors, but not leukemic cells, from fluorouracil provided a more effective treatment than conventional induction therapy in mouse models of acute myeloid leukemia. This strategy has the potential to be extended for use in other cancers where FLT3 inhibition does not adversely affect the effectiveness of chemotherapy. Thus, the addition of quizartinib to cancer treatment regimens could markedly improve cancer patient survival and quality of life.

U2 - 10.1126/scitranslmed.aam8060

DO - 10.1126/scitranslmed.aam8060

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

M1 - aam8060

ER -